Published in Cancer Immunol Immunother on November 10, 2013
Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother Cancer (2016) 1.22
Isolation and characterization of CD34+ blast-derived exosomes in acute myeloid leukemia. PLoS One (2014) 0.99
Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunol Immunother (2015) 0.99
What makes a blood cell based miRNA expression pattern disease specific?--a miRNome analysis of blood cell subsets in lung cancer patients and healthy controls. Oncotarget (2014) 0.99
Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Clin Cancer Res (2014) 0.97
Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Cancer Sci (2015) 0.97
Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. Head Neck (2016) 0.94
Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells. J Immunol (2015) 0.89
Reversing T-cell Dysfunction and Exhaustion in Cancer. Clin Cancer Res (2016) 0.88
mTOR signaling, Tregs and immune modulation. Immunotherapy (2014) 0.82
The role of regulatory T cells in cancer immunology. Immunotargets Ther (2015) 0.82
The Treg/Th17 paradigm in lung cancer. J Immunol Res (2014) 0.82
The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis. Breast Cancer Res Treat (2015) 0.81
Crosstalk of carcinoembryonic antigen and transforming growth factor-β via their receptors: comparing human and canine cancer. Cancer Immunol Immunother (2015) 0.81
Disturbed Th17/Treg Balance in Patients with Non-small Cell Lung Cancer. Inflammation (2015) 0.80
Clinical Impact of Regulatory T cells (Treg) in Cancer and HIV. Cancer Microenviron (2014) 0.80
Anti-GITR therapy promotes immunity against malignant glioma in a murine model. Cancer Immunol Immunother (2016) 0.78
IL-10 and ARG-1 concentrations in bone marrow and peripheral blood of metastatic neuroblastoma patients do not associate with clinical outcome. J Immunol Res (2015) 0.78
Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients. Sci Rep (2016) 0.77
Inflammation, cytokines, the IL-17/IL-6/STAT3/NF-κB axis, and tumorigenesis. Drug Des Devel Ther (2015) 0.77
Metabolomics Analysis of Hormone-Responsive and Triple-Negative Breast Cancer Cell Responses to Paclitaxel Identify Key Metabolic Differences. J Proteome Res (2016) 0.77
Cancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant State. Vaccines (Basel) (2015) 0.77
Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles. Viruses (2015) 0.77
Transforming growth factor-β1 sustains the survival of Foxp3(+) regulatory cells during late phase of oropharyngeal candidiasis infection. Mucosal Immunol (2015) 0.77
Diffuse alveolar hemorrhage after erlotinib combined with concurrent chemoradiotherapy in a patient with esophageal carcinoma. Int J Clin Exp Med (2014) 0.77
FOXP3 autoantibody as a potential early prognostic serum biomarker in patients with cervical cancer. Int J Clin Oncol (2015) 0.77
Translating Treg Therapy in Humanized Mice. Front Immunol (2015) 0.76
Rapamycin regulates iTreg function through CD39 and Runx1 pathways. J Immunol Res (2014) 0.76
Clinical Development of the E75 Vaccine in Breast Cancer. Breast Care (Basel) (2016) 0.75
CD4-Transgenic Zebrafish Reveal Tissue-Resident Th2- and Regulatory T Cell-like Populations and Diverse Mononuclear Phagocytes. J Immunol (2016) 0.75
Mechanism of immune evasion in breast cancer. Onco Targets Ther (2017) 0.75
Blood Genome-Wide Transcriptional Profiles of HER2 Negative Breast Cancers Patients. Mediators Inflamm (2016) 0.75
Analysis of the intensity of immune cell infiltration and immunoreactivity of RCAS1 in diffuse large B-cell lymphoma of the palatine tonsil and its microenvironment. Cell Tissue Res (2015) 0.75
Mesenchymal stem cells-regulated Treg cells suppress colitis-associated colorectal cancer. Stem Cell Res Ther (2015) 0.75
Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab. J Immunother Cancer (2016) 0.75
The Immune Landscapes of Polypoid and Nonpolypoid Precancerous Colorectal Lesions. PLoS One (2016) 0.75
Phenotypic analysis of T cells infiltrating colon cancers: Correlations with oncogenetic status. Oncoimmunology (2015) 0.75
Immunosuppression Induced by Chronic Inflammation and the Progression to Oral Squamous Cell Carcinoma. Mediators Inflamm (2016) 0.75
Endogenous immunity at the forefront of tumor dormancy. Future Sci OA (2015) 0.75
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med (2003) 26.05
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
How regulatory T cells work. Nat Rev Immunol (2008) 11.66
Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer (2005) 10.06
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med (2007) 10.00
Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med (1996) 8.54
Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol (2006) 6.23
Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity (2009) 6.11
Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood (2007) 6.03
Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol (2008) 6.01
Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol (2003) 5.47
Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res (2011) 5.30
The tumor microenvironment and its role in promoting tumor growth. Oncogene (2008) 4.66
Regulatory T cells in tumor immunity. Int J Cancer (2010) 4.53
GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity (2005) 4.53
Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol (2011) 4.29
Type 1 T regulatory cells. Immunol Rev (2001) 3.26
Extracellular adenosine triphosphate and adenosine in cancer. Oncogene (2010) 2.53
The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res (2012) 2.37
The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res (2007) 2.30
Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem (2009) 2.18
Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res (2011) 2.16
Regulatory T cells in cancer. Adv Cancer Res (2010) 2.02
Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells. Blood (2012) 2.00
Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature (2013) 1.99
Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood (2009) 1.93
Adenosine production by human B cells and B cell-mediated suppression of activated T cells. Blood (2013) 1.70
T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res (2008) 1.63
Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res (2007) 1.61
Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). Int J Oncol (2008) 1.58
Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Trans (2013) 1.42
The role of anti-inflammatory drugs in colorectal cancer. Annu Rev Med (2012) 1.40
AMP is an adenosine A1 receptor agonist. J Biol Chem (2012) 1.36
Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment. Cancer Immunol Immunother (2007) 1.30
The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer. Br J Cancer (2012) 1.25
Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem (2010) 1.25
Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities. Blood (2012) 1.23
Distinct regulatory CD4+T cell subsets; differences between naïve and antigen specific T regulatory cells. Curr Opin Immunol (2011) 1.18
Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Res (2011) 1.18
Induced and natural regulatory T cells in human cancer. Expert Opin Biol Ther (2012) 1.15
Regulatory T cells negatively affect IL-2 production of effector T cells through CD39/adenosine pathway in HIV infection. PLoS Pathog (2013) 1.10
Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancer. Clin Cancer Res (2013) 0.98
Adenosine and prostaglandin e2 production by human inducible regulatory T cells in health and disease. Front Immunol (2013) 0.92
Receptor desensitization and blockade of the suppressive effects of prostaglandin E(2) and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes. Cancer Immunol Immunother (2010) 0.92
CD4 (+)CD25 (+)Foxp3 (+) regulatory T cells and hematologic malignancies. Front Biosci (Schol Ed) (2010) 0.86